Forty Seven adds Nobel winner Jim Allison to a dream team of scientific advisers
Forty Seven has added immunology superstar and newly minted Nobel laureate Jim Allison to its advisory team.
The immuno-oncology startup said Wednesday that Allison will be joining its scientific advisory board, along with three other heavyweights from the research world: Stanford’s Ronald Levy, MD Anderson’s Padmanee Sharma, and Georgetown’s Louis Weiner.
The dream-team advisers will be guiding Forty Seven on development of its lead product, an investigational monoclonal antibody known as 5F9. The antibody targets the CD47 receptor, which the company describes as “a ‘don’t eat me receptor’ signal that cancer cells commandeer to avoid being ingested by microphages.” 5F9 is currently in Phase I/II testing for a variety of cancers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.